Table of frequent aberrant markers in AML

It is well recognised that marker expression in acute myeloid leukaemia may frequently include the expression of immunological markers not typically associated with myeloid lineage. Broadly, the abberant expression may include:

Markers of primitive phenotype that are more frequently associated with lymphoid disorders, most frequently, CD7 43% BCRABL TdT 7%

Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage CD2 CD4, 36 38 MONOCYTIC 5%

BASOPHILIC 123, 203, 11B 22

Frequent abberant markers in AML that are often associated with genetic/cytogenetic subtype: CD19 30% CBF RUNX1, BCRABL CD56 CBF RUNX1 NPM1 OFTEN LACK CD34